Hi! Some company words

Fusce elementum tristique leo, nec scelerisque lacus eleifend vel. Mauris vehicula urna sed quam vehicula, ac porta arcu molestie. Etiam in lectus lectus. Sed eget nibh a urna accumsan convallis venenatis ac massa. Donec tincidunt mattis pretium. Proin ac blandit ligula, et mattis diam. Nulla et mattis arcu, ut ullamcorper dolor. Donec porta sem nisi, eu scelerisque elit semper ac. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Duis malesuada ligula eget odio vulputate, quis imperdiet tortor pharetra. Aenean auctor lobortis ligula sit amet iaculis. Aenean accumsan nibh porttitor malesuada pellentesque. Nam justo urna, tempus a rhoncus nec, porta et lorem. Duis vel condimentum eros, sit amet tempus odio. Duis volutpat iaculis enim, eget malesuada urna fringilla eu. Praesent vel aliquam lorem.

Our contacts

Fusce dapibus, tellus commodo, tortor mauris condimentum utellus fermentum, porta sem.

Phone:    (212) 555 55 00 or (212) 555 55 00

Adress:    Company LTD Street nr 100, 4536534, Chicago, US


Innovative, cost-effective, "best in class" solutions to pressing problems in the global medical industry.


Click on the following products for more information

CITOFEM family of products

SPB family of products

ROSS-RU family of products

Product lines focus on the following categories:


bioTD is rapidly becoming a global leader in in vitro testing. Our liquid cytology products for cancer detection are recognized as highest quality at best value, marketed as:
• Combinations with molecular biology

Read more
Ross Ru™, SPB™

bioTD's Ross Ru™ family of products provides highly effective nanotechnology-based silver for skin discontinuities.

The SPB® family of products form an invisible protective film on the skin, blocking contact with irritants including latex and other proteins, as well as allergens and mildly corrosive material.

Read more

bioTD has a very interesting pipeline of products well advanced in the R&D process, as well as new service opportunties.

The company also eagerly seeks to in-license developments within specific categories.

Read more